Edwards Lifesciences (NYSE:EW) Reaches New 52-Week High – Should You Buy?

Edwards Lifesciences Corporation (NYSE:EW)’s share price reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $94.60 and last traded at $93.1050, with a volume of 222940 shares trading hands. The stock had previously closed at $94.37.

Analyst Upgrades and Downgrades

Several brokerages recently commented on EW. Barclays reissued an “overweight” rating and set a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Canaccord Genuity Group set a $85.00 price target on Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. BTIG Research lifted their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Evercore reissued an “outperform” rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a research note on Monday. Finally, Wall Street Zen lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $96.70.

Edwards Lifesciences Stock Down 0.4%

The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The stock has a market capitalization of $54.58 billion, a P/E ratio of 50.42, a PEG ratio of 2.39 and a beta of 0.86. The stock’s fifty day moving average is $86.13 and its two-hundred day moving average is $83.71.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.05. The company had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm’s revenue was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, research analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $91.40, for a total value of $56,576.60. Following the transaction, the vice president owned 40,411 shares of the company’s stock, valued at approximately $3,693,565.40. This trade represents a 1.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the business’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president owned 15,334 shares in the company, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 57,958 shares of company stock valued at $4,839,284. 0.31% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Edwards Lifesciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EW. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Edwards Lifesciences by 27.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 109,749 shares of the medical research company’s stock worth $9,356,000 after purchasing an additional 23,514 shares in the last quarter. Assenagon Asset Management S.A. grew its position in Edwards Lifesciences by 39.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 2,286,298 shares of the medical research company’s stock valued at $194,907,000 after purchasing an additional 648,870 shares in the last quarter. Central Pacific Bank Trust Division purchased a new position in Edwards Lifesciences during the fourth quarter valued at approximately $775,000. Sivik Global Healthcare LLC purchased a new stake in Edwards Lifesciences in the 4th quarter worth approximately $2,984,000. Finally, Stance Capital LLC lifted its position in Edwards Lifesciences by 373.1% in the 3rd quarter. Stance Capital LLC now owns 45,994 shares of the medical research company’s stock worth $3,577,000 after buying an additional 36,272 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.